trending Market Intelligence /marketintelligence/en/news-insights/trending/IFy6VakVb3DFjepGRUJaCA2 content esgSubNav
In This List

US FDA approves Pfizer's pain management drug

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


US FDA approves Pfizer's pain management drug

Pfizer Inc. said the U.S. Food and Drug Administration approved Lyrica extended-release tablets to treat two nerve-related pain conditions: postherpetic neuralgia and neuropathic pain associated with diabetic peripheral neuropathy.

The approval does not cover the treatment of fibromyalgia, which is characterized by musculoskeletal pain.

The approval was based on the results of a placebo-controlled clinical trial involving 801 patients. In the drug arm of the study, 73.6% of the patients achieved at least 50% improvement in pain intensity compared with 54.6% in the placebo group.

The most common adverse reactions reported were dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth and weight gain.